166 related articles for article (PubMed ID: 38010606)
1. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
Liu WD; Hou HA; Li KJ; Qin A; Tsai CY; Sheng WH
Adv Ther; 2024 Feb; 41(2):847-856. PubMed ID: 38010606
[TBL] [Abstract][Full Text] [Related]
2. Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan.
Chen KY; Lee KY; Qin A; Luo CS; Yeh YK; Zheng JQ; Chen CM; Tsai CY; Lin S; Liao J; Huang YW; Feng PH
Adv Ther; 2022 Feb; 39(2):910-922. PubMed ID: 34910280
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.
Liu WD; Feng PH; Cheng CY; Chou CL; Lee CH; Lu MC; Liu PY; Lee MH; Liao CH; Chen MC; Chen CP; Hsu SF; Tzeng YT; Lin YC; Ou TY; Qin A; Tsai CY; Shih WJ; Lee KY; Sheng WH
Infect Dis Ther; 2024 May; ():. PubMed ID: 38771550
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
[TBL] [Abstract][Full Text] [Related]
6. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
[TBL] [Abstract][Full Text] [Related]
8. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
9. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
Hsu SJ; Yu ML; Su CW; Peng CY; Chien RN; Lin HH; Lo GH; Su WW; Kuo HT; Hsu CW; Yang SS; Yang SS; Tseng KC; Qin A; Huang YW; Chuang WL
J Formos Med Assoc; 2021 Mar; 120(3):956-964. PubMed ID: 33077341
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
14. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
15. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
Huang YW; Hsu CW; Lu SN; Yu ML; Su CW; Su WW; Chien RN; Hsu CS; Hsu SJ; Lai HC; Qin A; Tseng KC; Chen PJ
Hepatol Int; 2020 Dec; 14(6):997-1008. PubMed ID: 33099752
[TBL] [Abstract][Full Text] [Related]
16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
17. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
[TBL] [Abstract][Full Text] [Related]
18. A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment.
Lo CC; Chuang WL; Kuo HT; Chen WM; Qin A; Tsai CY; Huang YW; Chen CY
J Formos Med Assoc; 2024 Jan; 123(1):55-61. PubMed ID: 37666718
[TBL] [Abstract][Full Text] [Related]
19. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.
Lin HH; Hsu SJ; Lu SN; Chuang WL; Hsu CW; Chien RN; Yang SS; Su WW; Wu JC; Lee TH; Peng CY; Tseng KC; Qin A; Huang YW; Chen PJ
JGH Open; 2021 Aug; 5(8):929-940. PubMed ID: 34386602
[TBL] [Abstract][Full Text] [Related]
20. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
Huang YW; Qin A; Fang J; Wang TF; Tsai CW; Lin KC; Teng CL; Larouche R
Br J Clin Pharmacol; 2022 May; 88(5):2396-2407. PubMed ID: 34907578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
